3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
7
Infections
7
Prostatic Neoplasms
4
Neutropenia
4
Lymphoma
4
Leukemia
4
Neoplasms, Plasma Cell
3
Febrile Neutropenia
3
Urinary Tract Infections
2
Pancreatic Neoplasms
2
Pancreatic Cyst
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Staphylococcal Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Recurrence
1
Rectal Neoplasms
1
Pulmonary Arterial Hypertension
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Pain
1
Interventions
Oxaliplatin
180
Capecitabine
174
Fluorouracil
154
Radiotherapy
107
Leucovorin
107
Irinotecan
93
Bevacizumab
69
Surgical Procedures, Operative
49
Cetuximab
39
Drug Therapy
38
Radiation
35
Neoadjuvant Therapy
33
Folfox protocol
29
Chemoradiotherapy
29
XELOX
22
Magnetic Resonance Spectroscopy
21
Chemotherapy, Adjuvant
21
Radiotherapy, Intensity-Modulated
19
Surveys and Questionnaires
17
Proctectomy
16
Biopsy
16
Early Intervention, Educational
14
trifluridine tipiracil drug combination
12
Panitumumab
12
Floxuridine
12
tislelizumab
11
regorafenib
11
Nivolumab
11
Laparoscopy
11
Celecoxib
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Rectal Neoplasms
×
Ciprofloxacin
×
Clear all
NCT02682485
2023-04-26
SES-DTA
University of Chicago
Phase 2
Withdrawn